NKCL Bio Group Co. Ltd.
(hereinafter referred to as NKCL Bio Group), a company specializing in
“personalized immune care”, will host the first Thanks Day for its partners at
Grand Ballroom of Grand Hyatt Seoul on February 22.
NKCL Bio Group is a biological
research company which researches and develops immune cell therapy products
using NK cells. NK cells, among various immune cells in the body, have the
strongest capacity to kill abnormal cells. In addition to research on cancer,
research is being actively carried out, specializing in infectious diseases of
viruses and other agents, autoimmune diseases, and anti-aging.
The first Thanks Day
would be an occasion to share with the partners, the company’s vision and the
research achievements over more than ten years of NKCL Bio Group, which has
built differentiated original technology through continuous research and
development in an unexplored field of NK cell therapy. NKCL Bio Group possesses
its own patents and technology on specialized NK cell culture, which use a kit
to add culture medium for NK cell culture. Recently, the company secured
patents and exclusive licenses for the immune cell treatment technology using
heterologous immune cells, and it is viewed that the company will take a
leading role of making the bio market more accessible to the public.
This event is hosted to
celebrate the completion of the GMP automated culture system and the opening of
the NK Immunotherapy Center.
The automated culture
system, completed in February, is an artificial intelligence-based, automatic
culture platform for immune cells, which provides a culture system optimized
for each individual. By receiving the GMP certification which meets the
standards in Korea, Europe, and the U.S., the company is preparing a strategy
to secure the global standards of the culture process and build future
The production, up to
now, of immune cell treatment relies on specialized research staff for the
entire process of customized culture, and there was a barrier to entry due to
high prices. NKCL Bio Group's automatic culture system is expected to dramatically
lower the cost of the expensive immune cell therapy by improving productivity
by more than 100 times, compared to the existing manual production method.
Meanwhile, NKCL Bio
Group is building various consumer platforms such as NK Human Immune Center, NK
Immune Cafes, and NK Immune Bakery Cafés in more than 140 locations nationwide,
in addition to immunotherapy centers through partnership with medical clinics
in Korea. Moreover, the company will renew this year its plan of moving into
the global market, after the plan had been halted due to COVID-19.
In 2020, the company already
signed a memorandum of agreement for NK cell therapy products with the
China-TSH Association, which has more than 500 clinics in China as its members.
NKCL Bio Group also entered into contracts with various global partners on “building
an NK cell culture center, a screening and treatment center and a platform’.
According to an official
at the Strategic Planning Team of NKCL Bio Group, “Starting with the research
and development of the cell therapy products in 2008, NKCL Bio Group secured
expertise and original technology of NK immune cell therapy through continuing
R&D. We expect market expansion and production with higher stability
through the completion of this GMP automated culture center.” The first Thanks
Day will be a hybrid event which invites about 300 VIPs and partners. The Zoom
live system and real-time streaming on YouTube will also be used to accommodate
about 3,000 guests. In line with the “contact-free” policy of the COVID-19 era,
many people are looking forward to the state-of-the-art method of the event hosting,
which simultaneously uses three channels of offline, Zoom, and YouTube. A lottery
event for online and offline participants will be also be offered.